Lupus News

The first proposed definition for disease modification in systemic lupus erythematosus, including lupus nephritis, requires “minimizing” disease activity with few treatment-associated toxicities, while slowing organ damage progression.

Iberdomide, a novel oral cereblon modulator, was superior to a placebo only in patients with systemic lupus erythematosus who received the highest dose in a phase 2 trial, albeit with a high incidence of adverse events, according to data.

Uncovering a viable biomarker in a historically challenging disease like lupus nephritis is tantamount to striking gold if it can be used for one important purpose: Predicting treatment response.

March is Autoimmune Awareness Month, and rheumatology organizations have been using their reach and influence on social media sites to spread the word and help patients with autoimmune diseases find community.

Patient-generated data gathered via social media surveillance may highlight unmet research needs and clinical care gaps for patients with lupus, including underrepresented groups, according to data published in Arthritis Care and Research.

Glucocorticoids can do a lot of harm over time. In this episode, John Stone, MD, MPH, walks us through the Glucocorticoid Toxicity Index, a validated tool to measure steroid toxicity over time that we’ll be seeing more of in the future.

Worse COVID-19 outcomes in patients with systemic lupus erythematosus are driven by comorbidities, demographics and untreated or active disease, according to data published in the Annals of the Rheumatic Diseases.

The American College of Rheumatology and the American Association of Hip and Knee Surgeons have released updated recommendations for the perioperative management of antirheumatic medication in patients undergoing hip and knee arthroplasty.

Patients with systemic lupus erythematosus are at double the risk for gestational diabetes during pregnancy compared with those without SLE, according to data published in The Journal of Rheumatology.

Growth impairment was reported in 23.6% of children with systemic lupus erythematosus, with corticosteroid duration and exposure prior to late puberty identified as key risk factors, according to data published in Pediatric Rheumatology.